A feedlot growth-performance trial and a metabolism trial were conducted to evaluate a dose response to ardacin (a glycopeptide antibiotic). Treatments consisted of an 88% concentrate finishing diet supplemented to contain (DM basis) 0, 8.25, 16.5., or 33 mg ardacin/kg. The growth-performance trial (129 d) involved 120 heifers and 120 steers in a randomized complete block design. There were no interactions (P less than .10) between sex and response to ardacin. Average daily gain increased (P less than .05) and DM conversion decreased (P less than .01) with increasing levels of ardacin supplementation. At the 33 mg/kg level of supplementation, ADG and DM conversion were improved 10.6 and 5.6%, respectively. Four Holstein steers (344 kg) with cannulas in the rumen and proximal duodenum were used to evaluate treatment effects on characteristics of digestion. There were cubic effects of ardacin on ruminal starch digestion (P less than .05), microbial N synthesis (MNS, P less than .10), and microbial efficiency (MNEFF, grams of MNS/kilogram of OM fermented). For the 16.5 and 33 mg/kg levels of supplementation, ruminal starch digestion was increased 4.9%, and MNS and MNEFF were decreased 12.9 and 15.6%, respectively. Postruminal and total tract digestion of N increased linearly (P less than .10) with ardacin supplementation. Total tract digestion of OM, ADF, and starch were not affected (P greater than .10). Ardacin did not influence (P greater than .10) ruminal pH or molar VFA proportions. It is concluded that supplementation of a finishing diet with 33 mg ardacin/kg will enhance ADG and DM conversion of feedlot steers and heifers.
scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.